Puma Biotechnology Inc (PBYI)

36.20
1.50 4.32
NASDAQ : Health Care
Prev Close 34.70
Open 34.35
Day Low/High 33.65 / 36.20
52 Wk Low/High 19.74 / 73.27
Volume 733.98K
Avg Volume 748.90K
Exchange NASDAQ
Shares Outstanding 36.82M
Market Cap 1.26B
EPS -7.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI

Newman Ferrara LLP Announces Corporate Governance Investigation Of Puma Biotechnology, Inc. - PBYI

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Puma Biotechnology, Inc.

Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients

Puma Biotechnology Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has expanded the fourth cohort from its Phase II SUMMIT clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with...

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology To Present At J.P. Morgan Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

First Week of PBYI February 2017 Options Trading

First Week of PBYI February 2017 Options Trading

Investors in Puma Biotechnology, Inc. saw new options begin trading this week, for the February 2017 expiration.

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology To Move Stock Exchange Listing To Nasdaq

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Stock Market.

Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)

Figure 1: Treatment Emergent Diarrhea By Month In ExteNET Versus CONTROL (Graphic: Business Wire)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2016 CTRC-AACR San...

Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents Results Of Biomarker Analysis Of Phase II Trial Of PB272 In Neoadjuvant Treatment Of HER2-Positive Locally Advanced Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that a biomarker analysis of the NSABP FB-7 Phase II clinical trial of Puma's investigational drug PB272 (neratinib) was presented at the 2016...

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology Presents Interim Results Of Phase II Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer At The 2016 San Antonio Breast Cancer Symposium

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that updated interim results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib), given as monotherapy and...

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards

Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.

Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States

Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, has initiated a Managed Access Program for PB272 (neratinib).

Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)

Puma Biotechnology Announces Presentations Of Investigational Data At The San Antonio Breast Cancer Symposium (SABCS)

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that its lead drug candidate PB272 (neratinib) will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium...

Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug

Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug

Monday's disclosure that Puma is adding a second drug to its diarrhea prophylaxis protocol for neratinib-treated patients once again raises concern that the drug is too toxic to be approved.

Puma Biotechnology Reports Third Quarter 2016 Financial Results

Puma Biotechnology Reports Third Quarter 2016 Financial Results

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2016.

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Closes $172 Million Public Offering Of Common Stock

Puma Biotechnology Closes $172 Million Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the closing of an underwritten public offering of 4,312,500 shares of its common stock at a price to the public of $40.

June 2017 Options Now Available For Puma Biotechnology (PBYI)

June 2017 Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the June 2017 expiration.

Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology Announces Underwriters' Full Exercise Of Option To Purchase Additional Shares

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble

Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology Prices Public Offering Of Common Stock

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $40.

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering

Puma Biotechnology (PBYI) is commencing a secondary public offering of stock.